Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.080 +0.020 (+1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Why Lexaria Bioscience (LEXX) Shares Are Moving
Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering. 
Via Benzinga
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D
Via Investor Brand Network
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on $3.6M Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial
Via Investor Brand Network
Exposures Product Safety
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap
Via Investor Brand Network
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria's Submits Investigational New Drug Application
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) To Hit High Ground in Q2 and Q3 2024 with Animal and Human GLP-1 Study Programs
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Shares Company Update in Annual Shareholder Letter
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Releases Annual Letter from the CEO
Via ACCESSWIRE
LEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024
Lexaria Bioscience just reported results for the first quarter of 2024. 
Via InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
From Lexaria Bioscience Corp.
Via GlobeNewswire
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
Via Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END 
Via FinancialNewsMedia
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
From Lexaria Bioscience Corp.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS